Functionalized biomaterials can work synergistically with natural or engineered immune cells for cancer immunotherapy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) engineered T cells has shown success and clinical approval for the treatment of B cell cancers 16 . However, for CAR T cells to fulfill their promising potential, particularly for targeting solid tumors 17, 18 , important challenges must be overcome to improve both efficacy [17] [18] [19] [20] and safety [21] [22] [23] [24] . For engineered anti-tumor T cells to achieve durable tumor remission in patients, a demanding manufacturing process is required to ensure the quantity and quality of the cell product for therapeutic use 1, [25] [26] [27] . To increase the tumor targeting specificity and 3 avoid "on-target, off-tumor" toxicity in bystander healthy tissues 28 , CAR-T cells have been engineered with combinatorial antigen AND-gate activation control that requires sensing two antigens on a target cell to initiate killing. The clinical application of this strategy, however, requires systematic identification of tumor specific antigen combinations and would also benefit from better control of cell activity 27, 29 .
Functionalized biomaterials can work synergistically with natural or engineered immune cells for cancer immunotherapy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) engineered T cells has shown success and clinical approval for the treatment of B cell cancers 16 . However, for CAR T cells to fulfill their promising potential, particularly for targeting solid tumors 17, 18 , important challenges must be overcome to improve both efficacy [17] [18] [19] [20] and safety [21] [22] [23] [24] . For engineered anti-tumor T cells to achieve durable tumor remission in patients, a demanding manufacturing process is required to ensure the quantity and quality of the cell product for therapeutic use 1, [25] [26] [27] . To increase the tumor targeting specificity and avoid "on-target, off-tumor" toxicity in bystander healthy tissues 28 , CAR-T cells have been engineered with combinatorial antigen AND-gate activation control that requires sensing two antigens on a target cell to initiate killing. The clinical application of this strategy, however, requires systematic identification of tumor specific antigen combinations and would also benefit from better control of cell activity 27, 29 .
Biomaterials functionalized with modulatory biomolecules at pre-specified densities have been shown to communicate with and control therapeutic immune cells both ex vivo and in vivo [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . For example, synthetic materials have been functionalized with agonistic antibodies for CD3 and CD28 to drive ex vivo T cell expansion 25, 26 .
However, biodegradable materials 25 with optimized material structure/composition and controlled surface moiety loading can provide unique opportunities to improve the ease of manufacturing and the quantity and quality of T cells produced. There is also a growing interest in the use of biomaterials for local modulation of engineered T cell activity in vivo during the course of treatment 1 .
Nonetheless, the use of biomaterials to precisely modulate immune cells still faces key challenges. There is a need for robust chemical conjugation strategies to surfacefunctionalize biodegradable materials with multiple signals (e.g. proteins/antibodies) at high densities and precisely controlled ratios [30] [31] [32] [33] . PEG (polyethylene glycol) is commonly used as a linker or scaffold for the surface conjugation of biomolecules 31 , but this method is limited by the inefficient presentation of functional groups for attaching biomolecules due to PEG's flexibility 34 . Synthetic short oligonucleotidesnatural polymers with controllable sequence and structure -have been used as surface scaffolds on metallic particles for siRNA delivery [34] [35] [36] [37] , but have yet to be fully utilized for modular payload assembly on biodegradable materials.
In this work, we developed short synthetic DNA scaffolds for the efficient and versatile functionalization of proteins or antibodies on the surface of biodegradable particles (Fig. 1a) . A series of optimization studies were carried out to achieve maximum loading density, ratiometric control of moiety loading, adaptability to different particle size/composition, and feasibility for in vivo use. Micron-sized artificial immune cell engagers (AICE) were made from biocompatible poly(lactic-coglycolic acid) (PLGA) polymer 38 (Fig. 1a) . We demonstrated that: i) we can load a range of immune modulators (e.g. anti-CD3, anti-CD28, and IL-2) on AICE at controlled ratios and densities; ii) the ratiometric control of costimulatory ligands is essential for optimal ex vivo T cell activation and expansion with higher yield and less exhaustion; iii) we can locally administer antigen-presenting AICE to control ANDgate CAR-T cell activation and tumor clearance in vivo (Fig. 1a) . This modular materials-based strategy can provide versatile and precise synthetic control of natural or engineered immune cells for cancer immunotherapy 1, 12, 29 .
RESULTS

Fabrication of surface DNA scaffolded polymeric particles
Synthetic short DNA strands were immobilized on the surface of polymeric particles to create an adaptable scaffold for loading bioactive molecules. The emulsion protocol of particle synthesis 38 was modified to add conjugated polymer-DNA amphiphilic molecules during the fabrication process such that the hydrophilic DNA segment distributes around the hydrophobic core upon sonication (Fig. 1b) . Polymer-DNA molecules were first synthesized through a conjugation of thiol-modified DNA to Maleimide (Mal)-modified polymer. We optimized the polymer, DNA length, solvent, and reaction conditions to generate optimal polymer-DNA molecules to form stable PLGA (50:50, MW 38-54k, Sigma) particles with dense DNA scaffolds ( Fig. Supplementary 1a-d ). PLGA10k-PEG5k-Mal was identified as an important polymer-DNA component to ultimately form microparticles of the desired size (1-2 μm in diameter), so we kept the polymer constant while varying the excess of DNA input during the conjugation reaction and observed an increase in polymer coupling efficiency (Fig. 1c) .
The direct incorporation of polymer-DNA reaction mixtures with different DNA:polymer ratios into the particle fabrication protocol yielded a significant increase of surface payload-attachable DNA scaffold density, as determined by a fluorescence-based hybridization analysis (Fig. 1d) . Strikingly, the highest average surface loading density on particles (~5 million DNA duplexes per particle, Fig.   Supplementary 1e-g ) was roughly analogous to the theoretical limit (at ~4 million by footprint calculation, based on ~2 nm diameter of DNA duplex) of a spherical particle with a 2 μm diameter. In particular, this hybridization-guided loading was about 27-fold more efficient than that from the traditional method
33
, in which thiol-modified DNA molecules were conjugated to surface-exposed Mal groups after particle fabrication using equal input amount of PLGA10k-PEG5k-Mal (Fig. 1d) . The hybridization-guided biomolecule assembly protocol was optimized to a 30-minute incubation at 37 o C (Fig. Supplementary 1h) , and functionalized particles can be further lyophilized for storage and transportation (Fig. Supplementary 1i) .
To accommodate diverse applications from intracellular payload delivery to extracellular signal transduction, DNA-scaffolded particles can be synthesized at various sizes and also loaded with biomolecules in their core. Particle size can be controlled by tuning key emulsion parameters ( Fig. 1e and Supplementary Fig. 1j ).
We observed a concave shape on one side for some larger particles (~2 μm in diameter) but not for smaller particles (~500 nm) (Fig. 1f) possibly due to the high surface hydrophilicity with DNA scaffolds leading to higher surface to volume ratio.
Additionally, we showed that the core of these DNA-scaffolded microparticles could also be loaded with biomolecules including oligonucleotides and peptides through a double-emulsion protocol ( Fig. 1g and Supplementary Fig. 1k ). This strategy of fabricating DNA-scaffolded particles was also successfully replicated using other polymers such as polylactic acid (PLA) (Fig. 1h and Fig. Supplementary 1l,m) .
Multi-functionalization of DNA-scaffolded particles
Biomolecules can be loaded on the surface of DNA-scaffolded particles using one of two strategies: a) linking functional groups of the scaffolds to biomolecules through the surface step-by-step conjugation via a bifunctional linker; and b) through the direct hybridization of complementary DNA-biomolecule conjugates to the scaffold (Fig. 2a) . In the case of a fluorescently labeled human IgG, the surface conjugation strategy resulted in saturated protein loading even with increased densities of available DNA linkers on surface (Fig 2b, Fig 1d and Fig. Supplementary 2a) . In contrast, the hybridization-guided assembly strategy showed a dramatically higher level of IgG loading for particles with denser DNA linkers, and the increase in IgG loading corresponded to the scaffold density (Fig. 2b) . The highest level of IgG loading achieved (at ~0.6 million per particle) was again comparable to the theoretical footprint limit of a spherical particle at 2 μm in diameter (~0.64 million per particle, based on ~5 nm diameter of IgG) (Fig. 2b) . For generating DNA-antibody conjugates with the minimum damage to the antibody activity, different chemistries ( Fig.   Supplementary 2b ,c) were attempted and the "TCEP" strategy 6 was identified as optimal, whereby the antibody hinge region was selectively reduced to expose the thiol group for 3'NH 2 -modified complimentary DNA to attach through a MALdPEG4-NHS linker (Quanta Biodesign). For example, anti-PD-L1 antibody conjugated with DNA through this strategy showed intact binding activity ( Fig.   Supplementary 2c) , and its loading on PLGA microparticles resulted in high binding specificity for PD-L1 positive cells (Fig. 2c) . For DNA tethering of proteins other than antibodies, other options are available to yield products with intact activity (Fig.   Supplementary 2d,e) .
Another advantageous feature of using DNA as a surface scaffold is that the uniqueness of nucleotide sequences enables the independent control of loading multiple cargos on the same material surface (Fig 2d) . Polymer-DNA conjugates with three distinct DNA sequences (namely R, G, and B strand) that do not anneal with each other (Fig. Supplementary 2f ) were synthesized and incorporated into particle emulsion with reaction mixtures at different ratios (3:1:1, 1:1:1 and 1:1:3). After surface hybridization with a mixture of their respective dye-labeled complementary strands ( Fig. 2d) , we found that the ratios of hybridized DNA scaffolds of different sequences on PLGA microparticles were consistent with the polymer-DNA conjugate input, evidenced by both confocal fluorescence imaging (Fig. 2e) and a fluorescencebased quantification assay (Fig. 2f) . The ratiometric control of dye-labeled DNA strand loading was equally efficient for PLA microparticles (Fig. Supplementary   2g,h ). Based on this, we co-loaded three different proteins (GFP and two antibodies), each individually attached with one of the three complementary DNA strands, onto PLGA microparticles with varying ratios of the DNA surface scaffold sequences above. Similar distribution of each protein cargo compared with the scaffold population was observed (Fig. 2g) , demonstrating the robust ratiometric control of surface protein loading using this particle synthesis strategy.
To enable in vivo use, we explored the stability of the DNA scaffolds on the surface of PLGA microparticles in the presence of a large excess of DNase. (Fig. 2h) . We observed an almost complete (~87%) degradation of DNA scaffolds after DNase treatment; however, this dropped down to ~20% with IgG molecules conjugated to the scaffolds through the surface step-by-step conjugation (~1/4 of the highest IgG loading through hybridization-guided assembly) (Fig. 2b,i) . This suggests that the surface-loaded proteins are able to protect the DNA scaffolds. In human serum, we did not observe as significant DNA degradation for the naked particles due to the lower DNase concentration in serum than used in Fig.2i ; however, the degree of DNA degradation similarly decreased as surface payload proteins were attached (Fig. 2j) .
Macrophage uptake is a major obstacle 39 for particle-based drug delivery in vivo, therefore we incorporated a CD47-mimic "self"-peptide 40 on PLGA microparticles (Fig. 2k) . Fluorescein-labeled PLGA microparticles with and without surface-loaded "self"-peptide were co-incubated with a mouse macrophage line J774A.1 in vitro. The particle uptake assay showed that the "self"-peptide decoration significantly reduced the uptake of particles by macrophages ( Fig. 2k and Supplementary Fig 2i,j) . This "self"-peptide functionalization provides a possible strategy to reduce the clearance of particles in vivo.
Design of particles with ratiometrically controlled moieties for ex vivo human T cell activation
Given the ability to synthesize particles with ratiometric control of multiple surface cargos, we loaded anti-CD3 and anti-CD28 antibodies on AICE (PLGA microparticles) at varying ratios from 1:5 to 5:1. Anti-CD3/CD28 AICE were compared to commercial anti-CD3/CD28 Dynabeads at the same particle to cell ratio for the ability to expand human primary T cells with minimized differentiation and exhaustion (Fig. 3a) . Functionalized AICE activated T cells (Fig. 3b) and yielded higher or equivalent T cell expansion compared to Dynabeads expansion across three human T cell donors (Fig. 3c,d Fig. 3c and Fig. Supplementary 3a) . The phenotype of expanded T cells at day 14 was then explored by measuring expression of CD45RA and CCR7 surface markers (Fig. 3e) Fig. 3f and Fig. Supplementary 3b) corresponding to the cell expansion trend among AICE with different anti-CD3 to anti-CD28 ratios (Fig. 3c) . Through staining for T cell exhaustion markers LAG-3, PD-1 and TIM-3,
we found that the population of exhausted cells at the optimal condition AICE- [3:1] was generally less than those activated by Dynabeads among the three donors ( Fig.   Supplementary 3c,d ). Taken together, the data demonstrates that the surface ratio control of functional moieties on synthetic materials is important for the quantity and phenotype of cells yielded from ex vivo T cell expansion.
As an alternative to the standard protocol of supplementing free IL-2 in the media for ex vivo T cell culture 25 , we loaded IL-2 on AICE through the surface presentation via its antibody clone #5355 (Fig. Supplementary 3e) . This particular anti-IL-2
antibody was engineered to facilitate the binding of IL-2 to its β and γ receptor on T cells thus promoting the proliferation of non-Treg T cells 41 ( Fig. 3g and Fig.   Supplementary 3f) . Using the optimal condition of AICE[3:1] (anti-CD3:anti-CD28) determined above, we compared primary T cell expansion by supplementing equal amount of free IL-2 versus surface bound IL-2 ( Fig. Supplementary 3e) . Surface IL-2 loading enhanced CD4+ and CD8+ T cell expansion, and particularly improved expansion of CD4+ primary T cells after day 8 (Fig. 3h,i and Fig. Supplementary 3a ,g). Although with higher level of cell yield, the populations of LAG-3 and PD-1 positive CD4+ T cells still decreased in the two tested donors (Fig. Supplementary   3h ), demonstrating the advantages of AICE-surface presentation of IL-2 for ex vivo expansion.
Design of particles to prime activation of AND-gate CAR-T cells
We also explored the use of AICE coated with an orthogonal antigen (GFP) to prime AND-gate CAR-T cell tumor recognition circuits, with the goal of preventing "ontarget off-tumor" toxicity by restricting cell killing to tumors locally-injected with AICE microparticles (Fig 4a) . These AND-gate T cells utilize a modular synthetic IFN-γ, respectively) after 48 hours of co-culture with both HER2+ A375 cells and GFP+ AICE (Fig. 4c) . Increasing AICE GFP density led to elevated levels of cytokine secretion (Fig. 4c, Fig. Supplementary 4a) . Noticeably, T cells secreted significantly more cytokines with AICE presenting synNotch-priming GFP than with target cells presenting both synNotch and CAR antigens (A375 with GFP and HER2 co-expressed) (Fig. Supplementary 4b ).
Human primary CD8+ T cells containing the same circuit as above also showed AND-gate killing behavior, selectively killing HER2+ A375 cells in the presence of GFP+ AICE microparticles. Co-incubation of GFP+ AICE and CD8+ human primary T cells led to some killing of co-cultured HER2+ A375 cells (with 1:1 ratio) at 24 hours ( Fig. 4d,e) , and the killing became more apparent after 48 hours with higher densities of priming signals on AICE ( Fig. 4f and Fig. Supplementary 4c-f ). In contrast, initial attempts using particles synthesized by traditional conjugation chemistry and with far lower GFP density failed to activate AND-gate CAR-T cells, likely due to the inadequate ligand density for robust synNotch activation. As a demonstration of adaptability for translational use, a synthetic short peptide (PNE peptide) computationally predicted to be non-immunogenic 42 was engineered on AICE and co-incubated with its corresponding anti-PNE synNotch/anti-HER2 CAR CD8+ T cells and HER2+ target cells, and killing was significantly enhanced by PNE+ AICE addition (Fig. Supplementary 4g) . The co-incubation of target cells with synNotch CAR-T cells in the absence of AICE also showed moderate cytotoxicity ( Fig. 4f and Fig. Supplementary 4c-g ), which is likely due to the leakiness of inducible CAR expression also observed from previous reports and can be improved through further optimization of synNotch receptors.
Local tumor eradication in mouse model by the combinatorial treatment of priming particles and AND-gate T cells
To determine the feasibility of using local particle injections to send spatially-defined signals to therapeutic cells in vivo, we first monitored the distribution of intratumorally-injected AICE microparticles. We labeled surface DNA and polymer core with two distinct infrared dyes (Quasar705 and IR800CW respectively, We hypothesized that AICE made of GFP decorated PLGA microparticles could be injected intratumorally as a local activator for systemically administered anti-GFP synNotch/anti-HER2 CAR T cells (Fig. 5c) . NSG mice were implanted subcutaneously with the same HER2-overexpressed K562 xenograft tumors in bilateral flanks as a model for a tumor and healthy tissue both expressing the CAR antigen. After a week, mice were administered synNotch CAR-T cells once intravenously in combination with AICE intratumorally injected for 4 doses (Fig. 5c ).
The size of AICE-injected ipsilateral tumors decreased over time, in contrast to the contralateral tumors within the same mice without AICE injection and tumors in mice injected with AICE plus untransduced primary T cells (Fig. 5d-g ). We also performed fluorescence microscopy on fixed tumor samples of mice sacrificed at an early timepoint and observed selective T cell infiltration in the AICE-injected tumor ( Fig.   5h and Supplementary 5f ). These results demonstrate that AICE can provide a spatially controlled signal in vivo for the local activation of synNotch CAR-T cells and induction of precision tumor clearance with limited risk of cross-reaction against healthy tissues.
DISCUSSION
In this work, we demonstrate a unique platform using synthetic short DNA oligonucleotides as surface scaffolds on biodegradable materials for the precise and controlled loading of multiple biomolecules at specific ratio and density. These advanced biomaterials possess the ability to regulate immune cells in the context of ex vivo and in vivo activation of both natural and engineered T cells. Here we explored using a natural polymer, DNA, as the surface scaffold for loading biomolecules onto particles. We demonstrated, through near surface-saturated biomolecule loading and precise ratiometric control of moiety loading, that hybridization-based thermodynamics can overcome limitations of traditional surface conjugation such as reduced efficiency of multi-step reactions, steric hindrance, and decay of functional groups. The increased loading density of surface biomolecules was found to be necessary to make particles capable of presenting antigens to robustly activate synNotch receptors in primary human T cells, and may also significantly enhance immune cell signaling where ligand clustering is required 10, 46 . We also show the versatility of this strategy by fabricating particles of different sizes, as well as compositions with different degradation profiles. This method can be applied to other formats of biomaterial functionalization (e.g. scaffolds and nonspherical particles)
where fragile biomolecules need to be presented at a material interface.
The densely-packed surface DNA scaffolds and the payload attachments protected DNA linkers from enzymatic degradation, which shows great promise for in vivo use.
This organized packing of the particle surface with a protein corona may also minimize interactions with serum proteins to prevent macrophage clearance 47 .
Furthermore, particle uptake by macrophages can be attenuated through the immobilization of a CD47 mimic "self"-peptide 40 . Safety concerns about immunogenicity from the DNA scaffolds can be addressed through optimization of sequences and special modifications 48 .
The precise ratio of agonistic antibodies (anti-CD3 and anti-CD28) for T cell activation on AICE impacts ex vivo T expansion efficiency, as well as T cell differentiation and exhaustion phenotypes. The ability to accurately control the ratio of multi-cargo particle loading should enable identification of novel, precise combinations of modulatory signals that lead to diversified and improved T cell behavior. The use of biodegradable materials also omits the need for synthetic material removal prior to cell implantation. Cumulatively, these properties suggest that AICE could aid in manufacturing for ACT by improving the ease-of-production and fine-tuning the yield and phenotype of the therapeutic cell product.
We and other groups have developed strategies to engineer T cells with multiple receptors to detect combinations of antigens [27] [28] [29] We believe that the true promise of the AICE platform will be realized by using particles to present multiple signals within the tumor microenvironment. AICE particles could kick-start tumor killing by triggering CAR expression by synNotch-CAR T cells. T cell activity within the tumor could be further augmented by cofunctionalization of AICE particles with additional cargos that go beyond a synNotch ligand, for instance, a costimulatory ligand and a checkpoint inhibitor tailored to circumvent the specific immune evasion mechanisms of a particular tumor type 17, 45 .
Ultimately, it would be ideal to utilize intratumoral injection of AICE particles to initiate antigen-specific local immunity that could be converted into antigen spreading and systemic immunity by incorporating other cues onto/into the particles to stimulate innate immunity 18 .
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Fabrication of polymeric particles with DNA scaffolds For the fabrication of PLGA particles with varying sizes (Fig. Supplementary 1j) PLA microparticles fabrication used the same protocol but adjusted emulsion mixture: 0.5 mL dichloromethane (DCM) with 100 mg/mL polylactic acid (Mw 60,000, Sigma #38534), 0.5 mL aqueous buffer (10 mM sodium citrate, 600 mM Na His-tag GFP were expressed by Escherichia coli BL21 (DE3) (Novagen)
transduced with pRSET-EmGFP vector (ThermoFisher, #V35320) in E. coli expression medium (MagicMedia, Invitrogen #K6803), and extracted using cell lysis reagent (Sigma, #B7435) followed by the purification using nickel-nitrilotriacetic acid affinity chromatography (Invitrogen #R90115). The MAL-PEG4-NHS linker (Quanta Biodesign) was mixed with GFP at 30-fold molar excess, and incubated at 37°C for 1 hour followed by the size-exclusion chromatography to remove the excess. 3'Thiolmodified complementary DNA was decapped using the protocol described above, and reacted with modified GFP at 1:10 molar ratio at 37°C for 1 hour followed by 4°C
overnight. The next day, GFP-DNA conjugates are purified using nickelnitrilotriacetic acid affinity chromatography to remove unconjugated DNA. Protein-DNA conjugates were analyzed through SDS-PAGE gel electrophoresis (Genscript #M42012L) with SYPRO Ruby dye staining (ThermoFisher #S21900).
Ratiometric control of surface DNA scaffolds with different sequences and the co-loading of versatile payloads 3'Thiolated DNA with different sequences were synthesized, namely R, G, and B (Fig. Supplementary 2f) . Following the conjugation with PLGA10k-PEG5k-Mal (Akina, #AI053), polymer-DNA molecules from different sequences were mixed at varying ratios and incorporated into the particle fabrication process described above (100 nmol for each reactant).
Complementary strands to the DNA scaffolds that were pre-conjugated CD4+ and CD8+ T Cells numbers were quantified using a cell counter (Countess II FL AMQAF1000, ThermoFisher) every other day from day 6 to day 14 after AICE activation. Fresh IL-2 containing medium was supplemented to maintain the cell concentration between 0.5-1.5 million per mL. On day 14, T cell phenotype was studied by flow cytometry using the following antibodies: anti-CCR7 (BD #561271),
anti-CD45RA (BD #562885), anti-LAG-3 (BD #565720), anti-TIM-3 (BD #565558),
anti-PD-1 (Biolegend #329936).
Anti-IL-2 clone #5355 (ThermoFisher #MA523696) was biotinylated using NHS- Data availability. The authors declare that the data supporting the findings of this study are available within the paper (and its supplementary information files).
